Low AMH Treatment in Ahmedabad — Your Own Eggs First, Always

Anti-Müllerian Hormone (AMH) is a protein hormone produced by the small follicles in the ovaries. Because these follicles contain the eggs that will eventually be recruited for ovulation, the level of AMH in the blood gives us an indirect measurement of how many eggs remain in the ovarian reserve — what fertility specialists call the ‘ovarian reserve.’

AMH is one of the most useful fertility blood tests because, unlike FSH or oestrogen, it does not fluctuate significantly during the menstrual cycle. This means it can be tested on any day of your cycle and gives a consistent, reliable picture of your remaining egg quantity.

Learn how low AMH affects fertility, pregnancy chances, and the treatment options available to improve outcomes.

The Most Important Thing to Understand: AMH Measures Quantity, NOT Quality

This is the most critical distinction in low AMH management, and one that is frequently  misunderstood — even by some clinicians.

AMH tells us how many eggs you have remaining. It does not tell us about the genetic quality or developmental potential of those eggs. A woman with AMH of 0.4 ng/mL may have 3–4 eggs retrieved in an IVF cycle — but if those eggs fertilise normally and develop into good-quality embryos, the success rate per embryo transferred is not significantly different from a woman with a higher AMH.

The challenge with low AMH is not egg quality — it is egg quantity per cycle. Fewer eggs means fewer chances per stimulation. This is precisely why our advanced protocols (Dual Stimulation and Embryo Banking) exist: to maximise the total number of eggs collected, cycle by cycle, until we have enough good-quality embryos to attempt transfer.

Low AMH can result from several different factors. Understanding the underlying cause matters, because it may influence the treatment approach:

• Age: The most common cause. AMH levels decline naturally and progressively from a woman’s mid-20s, with the steepest decline occurring from the mid-30s onward. This is a biological reality, not a disease.
• Endometriosis and Endometriomas: Chocolate cysts on the varies directly damage the surrounding follicular tissue, reducing AMH. Poorly performed cyst surgery can further reduce reserve. See our Endometriosis Treatment in Ahmedabad page for detail on reserve-protecting surgical approach.
• Previous Ovarian Surgery: Any surgery on the ovary — including cystectomy, ovarian drilling for PCOS, or surgery for torsion — can reduce the ovarian cortex and lower AMH.
• Cancer Treatment: Chemotherapy and pelvic radiotherapy are toxic to follicles and can cause rapid, severe reduction in AMH — sometimes leading to premature ovarian insufficiency.
• Autoimmune Conditions: The immune system can attack ovarian tissue in certain autoimmune conditions, reducing AMH over time.
• Genetics: A family history of early menopause (before age 45) is a significant predictor of earlier-than-normal decline in ovarian reserve.
• Idiopathic (Unknown Cause): In some women, particularly those under 35 with low AMH and no other identifiable cause, the reduction in reserve is unexplained. This is sometimes called Diminished Ovarian Reserve (DOR) and requires specialist management.

When a woman with low AMH comes to Wellspring IVF, the conversation does not begin with donor eggs. It begins with a thorough assessment of what her ovaries are genuinely capable of — and then with a protocol specifically designed to maximise that capability.

Low-AMH IVF specialist Dr. Pranay Shah has developed specialized protocol for poor responders that is used before any discussion of alternative options. See our full IVF Protocol for Low AMH for the detailed poor-responder protocol. This approach has two defining techniques:

Protocol 1: Dual Stimulation (DuoStim) — Two Chances in One Month

Dual Stimulation (DuoStim) is a breakthrough fertility protocol for poor responders with low AMH, designed to maximize egg yield within a single calendar month by utilizing both phases of the menstrual cycle.

• The Scientific Basis: Follicles grow not only during the follicular phase (days 1–14) but can also be stimulated in the luteal phase (days 15–28) of the same cycle.

• How It Works:

  • First Stimulation (Days 1–14): Standard follicular-phase stimulation followed by egg collection, embryo development, and vitrification (freezing).

  • Second Stimulation (Days 20–26): Luteal-phase stimulation begins about 5 days after the first egg collection, harvesting a second batch of eggs that same month.

• Key Benefits:

  • Double the Eggs & Embryos: Collects twice as many eggs as conventional single stimulation, increasing embryo yield from 1–2 up to 4–5.

  • No Compromise on Quality: Luteal phase-derived eggs show comparable fertilization rates and embryo quality to follicular phase eggs.

  • Time Efficiency: Combined with PGT-A for older patients, it helps identify viable embryos quickly, saving precious cycles and time.

Protocol 2: Embryo Banking — Accumulating Your Best Chances

Embryo Banking involves freezing all embryos from multiple stimulation cycles and accumulating them into a single cohort before performing a single transfer.

• The Logic: Instead of relying on the 1–2 eggs produced in a single cycle for low AMH patients, performing 2–3 stimulation cycles (often combined with DuoStim) allows patients to bank 4–6 high-quality frozen blastocysts.

• How It Works: A single Frozen Embryo Transfer (FET) is performed in an optimal, prepared uterine environment using the best embryo from the banked cohort.

• Key Benefits:

  • Higher Success Rates: Improves cumulative live birth rates compared to single-cycle transfers.

  • Enables PGT-A: Allows optional preimplantation genetic testing on the entire cohort to identify chromosomally normal embryos.

  • Optimized Uterine Environment: Avoids transferring into a freshly stimulated, suboptimal uterine lining.

  • Reduced Anxiety: Ensures a high-quality embryo is already waiting before a transfer cycle begins.

• Personalized Planning: Dr. Pranay Shah counsels patients on whether Embryo Banking, DuoStim, or a combination of both is ideal based on AMH, age, and response history.

At our Specialised Fertility Treatment Centre, beyond Dual Stimulation and Embryo Banking, Dr. Shah uses a comprehensive set of evidence-based interventions for women with low AMH:

• Individualised stimulation protocols: Standard antagonist protocols are often not optimal for poor responders. Dr. Shah may use modified protocols such as the ‘Bologna criteria’ protocol, mini-IVF, or modified natural cycle IVF depending on AMH level and previous response. For older patients, the embryo’s outer shell can thicken with age, and laser-assisted hatching may be considered at transfer.
• DHEA supplementation: Dehydroepiandrosterone (DHEA), typically 25–75 mg daily for 6–12 weeks before an IVF cycle, has evidence supporting improved ovarian response and egg quality in poor responders. It is prescribed selectively based on individual assessment.
• CoQ10 supplementation: Coenzyme Q10 supports mitochondrial function in oocytes, potentially improving egg quality. 200–600 mg daily for 2–3 months before IVF is often recommended for women over 35 with low reserve.
• Growth Hormone co-treatment: In selected poor responders, Growth Hormone (GH) is added to the IVF stimulation protocol. Evidence suggests it can improve ovarian response and egg yield in women who have previously had a poor response to standard stimulation.
• Antral Follicle Count (AFC) correlation: AMH is always interpreted alongside AFC on ultrasound. Sometimes AMH is disproportionately low relative to the visible follicle count — in such cases, the ovarian response may be better than the AMH level suggests.
• Natural Cycle IVF: For women with very low AMH (below 0.3 ng/mL) who produce very few follicles even with stimulation, Natural Cycle IVF — collecting the single naturally selected dominant egg each month — may offer a gentle, cost-effective way to accumulate embryos without the side effects of high-dose stimulation.
• If reserve is already declining and pregnancy isn’t yet on the table, egg freezing preserves the eggs you have now before the number falls further.

Our fertility specialists are committed to providing personalized, compassionate care with
the latest reproductive medicine techniques.

For the overwhelming majority of women with low AMH, the strategies above provide a genuine and often successful path to pregnancy with their own eggs. However, we believe in honest, transparent counselling — and there are situations where, after an exhaustive and genuine attempt with own eggs, the likelihood of success becomes very low.

In such circumstances, Dr. Shah will have a full, unhurried conversation about the remaining pathways. At Wellspring IVF, this conversation is always factual, never pressured, and always led by what is in your best interest — not by commercial considerations.

Donor Egg IVF as the next step — Important Information Under the ART (Regulation) Act, 2021

In India, the use of donor eggs in assisted reproduction is strictly regulated by the Assisted Reproductive Technology (Regulation) Act, 2021, and the rules framed thereunder. At Wellspring IVF, we follow these regulations completely and without exception.

Under the ART Act 2021, oocyte (egg) donation is permitted only through a registered ART Bank. Key provisions that patients must understand:

• Donor source: Eggs can only be obtained from registered, voluntary oocyte donors through an ART Bank registered under the ART Act 2021. Direct or known donation between individuals is not permitted under the Act.
• Voluntary donation: All donors are voluntary — they have provided informed consent to donate oocytes through the registered ART Bank system. Donors are never coerced or commercially exploited.
• Donor anonymity: Donor identity is maintained as per the provisions of the ART Act. The child born has the right to access non-identifying medical information about the donor.
• Medical screening: All donors registered with the ART Bank undergo comprehensive medical, genetic, and psychological screening as mandated by the Act.
• Matching: Matching between donor and recipient is performed considering physical characteristics as permitted under the Act and its guidelines.

We understand that reaching this conversation is emotionally significant. Dr. Shah and our counselling team will guide you through every aspect of this process — the medical procedure, the legal framework, the emotional considerations, and the realistic success rates — with complete transparency and compassion.

Low AMH sometimes occurs alongside other fertility conditions. A complete evaluation at Wellspring IVF ensures nothing is overlooked:

• Endometriosis — endometriomas directly damage ovarian tissue and reduce AMH. Reserve-protecting surgery is critical if intervention is needed.
• PCOD and PCOS — PCOS patients typically have high AMH (many follicles), but occasionally older PCOS patients can have declining reserve. Hormonal context must be evaluated separately.
• Uterine Fibroids — can impair implantation even when a good embryo is obtained through low AMH protocols.
• Blocked Fallopian Tubes — if tubes are blocked, IVF is the necessary route, making efficient egg collection from low-reserve ovaries even more critical.
• Male Factor Infertility — when both low AMH and a sperm issue are present simultaneously, the treatment strategy must be coordinated. See our Azoospermia Treatment and Oligospermia Treatment pages.